Europe’s approach to nicotine risk appears to be sending mixed signals. On 16 September, the European Parliament adopted its cardiovascular health strategy, in which differences in nicotine products and their risk profiles were recognised. Less than two weeks later, Parliament’s Committee on Public Health (SANT) adopted its report on the implementation of Europe’s Beating Cancer…
A recent JAMA Insights article on nicotine pouches provides a useful overview of the concerns and unanswered questions surrounding a rapidly growing category of smoke-free nicotine products. Published in 2026 by Thomas M. Piasecki, Megan E. Piper and Hasmeena Kathuria, the article examines patterns of nicotine pouch use in the United States, nicotine exposure, potential…
Public-health regulation frequently begins by identifying hazards. That is necessary, but identifying that a substance or product has the capacity to cause harm is not the same as establishing the level of risk associated with a particular pattern of use. This distinction matters increasingly in nicotine policy. Nicotine is addictive and is not risk-free, yet…
The European Union is reassessing whether its tobacco and nicotine framework remains fit for a market that has changed significantly since the Tobacco Products Directive (TPD) was adopted. Nicotine pouches, e-cigarettes, heated tobacco products and other novel products have expanded rapidly, creating regulatory questions that the existing framework does not address consistently. One possibility receiving…
When adults attempt to stop smoking using nicotine replacement therapy, e-cigarettes or other non-combustible nicotine products, one practical question quickly emerges: how much nicotine is enough? The answer matters because cigarette dependence varies considerably between smokers. Two people who smoke the same number of cigarettes each day may not absorb the same amount of nicotine…
The debate over nicotine pouches in India is increasingly becoming a debate about regulatory classification. Tobacco-free nicotine pouches do not fit comfortably within some of the legal categories created for cigarettes, smokeless tobacco, electronic cigarettes or medicinal nicotine products. Recent commentary has therefore focused on whether existing Indian laws adequately cover them and which authorities…
The scientific evidence surrounding smoke-free nicotine products is only one part of the challenge facing the nicotine sector. Even where manufacturers believe the evidence supports differentiated approaches to regulation, that evidence does not automatically translate into public understanding, regulatory acceptance or proportionate policy. That disconnect was at the centre of the GINN panel “We’re Right…
GINN Panel | InterTabac Dortmund 2026 Moderator: Joel Rubenstein, GINN Panelists: Tomasz Płaska, Chemnovatic; Jack Li, HG Innovation; Shivam Bihani, Satyam’s Sun Products (MYNT) The following transcript has been lightly edited for clarity and readability while preserving the substance and meaning of the speakers’ remarks. Introductions Joel Rubenstein: Hello, everybody. We’re going to shift…
PouchXchange 2026 | Dortmund I feel like Shem gave me a really great intro, as did my colleague there. This is not what I had signed up for, but we’re here! So, I’m hoping, if you allow me 10 minutes, I’ll give you a bit of a view from us at Dholakia Tobacco and RUSH:…
Reporting contributed by Kiran Sidhu “There is definitely an opportunity to foster collaboration among all the different stakeholders in the industry, from the manufacturers and independent research companies, to build an evidence-based toolkit that can be utilised when facing regulators,” said Monica Andrade De Orbe. De Orbe was hosting a panel titled, ‘Making…